Crewe Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$37.5K Buy
120
+26
+28% +$7.69K ﹤0.01% 486
2026
Q2
$29.7K Sell
94
-87
-48% -$20.5K ﹤0.01% 530
2026
Q1
$36.1K Buy
181
+39
+27% +$7.72K ﹤0.01% 408
2025
Q4
$26.8K Buy
142
+9
+7% +$1.73K ﹤0.01% 435
2025
Q3
$23.6K Buy
+133
New +$19.8K ﹤0.01% 468
2024
Q3
– Sell
-207
Closed -$17.4K – 865
2024
Q2
$17.4K Buy
+207
New +$16.5K ﹤0.01% 579

Other funds holding LGND

Crewe Advisors's LGND Position: Q3 2026 in Review

Crewe Advisors increased its Ligand Pharmaceuticals (LGND) stake by 28% in Q3 2026, buying an estimated $7.69K and bringing the position to 120 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #486.

Crewe Advisors first reported a position in LGND in Q2 2024 and has held it in 6 quarters since. 434 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Crewe Advisors held 120 shares of Ligand Pharmaceuticals worth $37.5K as of Q3 2026.
  • Crewe Advisors bought 26 Ligand Pharmaceuticals shares in Q3 2026, an estimated $7.69K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Crewe Advisors's portfolio in Q3 2026, its #486 holding.
  • Crewe Advisors first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • 434 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Crewe Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.